Alexandra Desvignes , Stéphane Zuily , Leilah Saadi , Pierre Olivier , Denis Regent , Hélène Schuhmacher , Denis Wahl
{"title":"FDG-PET监测难治性系统性结节病对英夫利昔单抗的早期反应","authors":"Alexandra Desvignes , Stéphane Zuily , Leilah Saadi , Pierre Olivier , Denis Regent , Hélène Schuhmacher , Denis Wahl","doi":"10.1016/j.rmedx.2007.09.004","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p><span>Systemic sarcoidosis can result in dramatic manifestations despite therapeutic escalation. </span>Tumor necrosis factor (TNFα) has a key role in this disease and antagonists of TNFα have been successfully used as an alternative to conventional therapy. We report a case of refractory sarcoidosis with mediastinal, bone and ear, nose, throat (ENT) lesions.</p></div><div><h3>Methods</h3><p><span><span>In this patient we monitored response to treatment by infusions of the anti-TNFα antibody, </span>infliximab, with fluorine 18-fluorodeoxyglucose </span>positron emission tomography (FDG-PET).</p></div><div><h3>Results</h3><p>Early and spectacular response to infliximab was demonstrated by FDG-PET, which evidenced complete response to treatment.</p></div><div><h3>Conclusion</h3><p>This case supports use of FDG-PET to evaluate the extent of active disease in refractory sarcoidosis and above all, FDG-PET could be an imaging method of choice showing response to infliximab in refractory sarcoidosis earlier than other imaging techniques.</p></div>","PeriodicalId":101082,"journal":{"name":"Respiratory Medicine Extra","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.rmedx.2007.09.004","citationCount":"1","resultStr":"{\"title\":\"FDG-PET to monitor early response to infliximab in refractory systemic sarcoidosis\",\"authors\":\"Alexandra Desvignes , Stéphane Zuily , Leilah Saadi , Pierre Olivier , Denis Regent , Hélène Schuhmacher , Denis Wahl\",\"doi\":\"10.1016/j.rmedx.2007.09.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p><span>Systemic sarcoidosis can result in dramatic manifestations despite therapeutic escalation. </span>Tumor necrosis factor (TNFα) has a key role in this disease and antagonists of TNFα have been successfully used as an alternative to conventional therapy. We report a case of refractory sarcoidosis with mediastinal, bone and ear, nose, throat (ENT) lesions.</p></div><div><h3>Methods</h3><p><span><span>In this patient we monitored response to treatment by infusions of the anti-TNFα antibody, </span>infliximab, with fluorine 18-fluorodeoxyglucose </span>positron emission tomography (FDG-PET).</p></div><div><h3>Results</h3><p>Early and spectacular response to infliximab was demonstrated by FDG-PET, which evidenced complete response to treatment.</p></div><div><h3>Conclusion</h3><p>This case supports use of FDG-PET to evaluate the extent of active disease in refractory sarcoidosis and above all, FDG-PET could be an imaging method of choice showing response to infliximab in refractory sarcoidosis earlier than other imaging techniques.</p></div>\",\"PeriodicalId\":101082,\"journal\":{\"name\":\"Respiratory Medicine Extra\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2007-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.rmedx.2007.09.004\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Respiratory Medicine Extra\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1744904907000537\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respiratory Medicine Extra","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1744904907000537","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
FDG-PET to monitor early response to infliximab in refractory systemic sarcoidosis
Background
Systemic sarcoidosis can result in dramatic manifestations despite therapeutic escalation. Tumor necrosis factor (TNFα) has a key role in this disease and antagonists of TNFα have been successfully used as an alternative to conventional therapy. We report a case of refractory sarcoidosis with mediastinal, bone and ear, nose, throat (ENT) lesions.
Methods
In this patient we monitored response to treatment by infusions of the anti-TNFα antibody, infliximab, with fluorine 18-fluorodeoxyglucose positron emission tomography (FDG-PET).
Results
Early and spectacular response to infliximab was demonstrated by FDG-PET, which evidenced complete response to treatment.
Conclusion
This case supports use of FDG-PET to evaluate the extent of active disease in refractory sarcoidosis and above all, FDG-PET could be an imaging method of choice showing response to infliximab in refractory sarcoidosis earlier than other imaging techniques.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
